Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP68 Anti-p21WAF1 (Ab-3) Mouse mAb (DF10)

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-SD11, Anti-p21, Anti-WAF, Anti-CIP1

OP68
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~21 kDa p21WAF1 protein in skin or colon tissue and in cells expressing wild-type p53 (e.g. Hs27 or U205 cells treated with DNA damaging agents).

Catalogue NumberOP68
Brand Family Calbiochem®
SynonymsAnti-SD11, Anti-p21, Anti-WAF, Anti-CIP1
References
ReferencesAgarwal, M.L., et al. 1995 Proc. Natl. Acad. Sci. USA 92, 8493.
Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
Deng, C., et al. 1995 Cell 82, 675.
El-Deiry, W.S., et al. 1995 Cancer Res. 55, 2910.
Waldman, T., et al. 1995 Cancer Res. 55, 5187.
El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
Elbendary, A., et al. 1994 Cell Growth Diff. 5, 1301.
Li, R., et al. 1994 Nature 371, 534.
Michieli, P., et al. 1994 Cancer Res. 54, 3391.
Noda, A., et al.1994. Exp. Cell Res. 211, 90.
El-Deiry, W.S., et al. 1993. Cell 75 817.
Gu, Y., et al. 1993. Nature 366, 707.
Harper, J.W., et al. 1993 Cell 75, 805.
Xiong, Y., et al. 1993. Genes Devel. 7, 1572.
Xiong, Y., et al. 1993. Nature 366, 701.
Xiong, Y., et al. 1992. Cell 71, 505.
Product Information
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Positive controlAny cell line expressing wild-type p53 (e.g. Hs27 or U2Os cells treated with DNA-damaging agents)
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Application ReferencesEpitope Identification Patrick O'Connor (NCI, personal communication).
Key Applications Immunoblotting (Western Blotting)
Immunoprecipitation
Application NotesImmunoblotting (1 µg/ml)
Immunoprecipitation (2 µg/sample)
Application CommentsMay also detect unidentified higher molecular weight proteins by immunoblotting. Maximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS cells with DNA damaging agents induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. This antibody can also immunoprecipitate proteins associated with p21WAF1. For immunoblotting applications, antigen/antibody complexes are best visualized using chemiluminescence. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenfull-length, recombinant human p21WAF1
ImmunogenHuman
Epitopewithin amino acids 58-77 of human p21WAF1
CloneDF10
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Yes
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
OP68 0

Documentation

Anti-p21WAF1 (Ab-3) Mouse mAb (DF10) SDS

Title

Safety Data Sheet (SDS) 

Anti-p21WAF1 (Ab-3) Mouse mAb (DF10) Certificates of Analysis

TitleLot Number
OP68

References

Reference overview
Agarwal, M.L., et al. 1995 Proc. Natl. Acad. Sci. USA 92, 8493.
Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
Deng, C., et al. 1995 Cell 82, 675.
El-Deiry, W.S., et al. 1995 Cancer Res. 55, 2910.
Waldman, T., et al. 1995 Cancer Res. 55, 5187.
El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
Elbendary, A., et al. 1994 Cell Growth Diff. 5, 1301.
Li, R., et al. 1994 Nature 371, 534.
Michieli, P., et al. 1994 Cancer Res. 54, 3391.
Noda, A., et al.1994. Exp. Cell Res. 211, 90.
El-Deiry, W.S., et al. 1993. Cell 75 817.
Gu, Y., et al. 1993. Nature 366, 707.
Harper, J.W., et al. 1993 Cell 75, 805.
Xiong, Y., et al. 1993. Genes Devel. 7, 1572.
Xiong, Y., et al. 1993. Nature 366, 701.
Xiong, Y., et al. 1992. Cell 71, 505.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision03-October-2007 RFH
SynonymsAnti-SD11, Anti-p21, Anti-WAF, Anti-CIP1
ApplicationImmunoblotting (1 µg/ml)
Immunoprecipitation (2 µg/sample)
DescriptionPurified mouse monoclonal antibody generated by immunizing F1 mice with the specified immunogen and fusing splenocytes with SP2/0 cells. Recognizes the ~21 kDa p21WAF1 protein.
BackgroundThe tumor suppressor p53 transcriptionally activates a number of genes including the WAF1/CIP1 gene in response to DNA damage. The ~21 kDa product of the WAF1 gene is found in a complex involving cyclins, cyclin dependent kinases (CDK), and PCNA in normal cells but not transformed cells and appears to be a universal inhibitor of CDK activity. One consequence of p21WAF1 binding to and inhibiting CDKs is to prevent CDK-dependent phosphorylation and subsequent inactivation of the Rb protein which is essential for cell cycle progression. p21WAF1 is, therefore, a potent and reversible inhibitor of cell cycle progression at both the G1 and G2 checkpoints, presumably to allow sufficient time for DNA repair to be completed. Irreversible G1 or G2 arrest leads to apoptosis. However, the role of p21WAF1 in apoptosis is less clear although p53-mediated apoptosis leads to increased WAF1 expression. Induction of p21WAF1 in response to DNA damage can occur by both p53-dependent and p53-independent mechanisms, in response to mitogenic stimuli, differentiation, or in tumor cells with mutated p53. Functional p21WAF1 is essential for p53-mediated G1 arrest presumably due to WAF1 inhibition of both CDK activity and PCNA-dependent DNA replication. WAF1 has also been identified as a gene involved in cellular senescence, termed sdi1. Not surprisingly, p21WAF1 overexpression is growth suppressive, consistent with its role as an inhibitor of CDKs. By inhibiting Rb inactivation in a p53-dependent fashion, p21WAF1 serves to integrate cell cycle control mediated by p53 and Rb.
HostMouse
Immunogen speciesHuman
Immunogenfull-length, recombinant human p21WAF1
Epitopewithin amino acids 58-77 of human p21WAF1
CloneDF10
IsotypeIgG₁
Specieshuman, not mouse, not rat
Positive controlAny cell line expressing wild-type p53 (e.g. Hs27 or U2Os cells treated with DNA-damaging agents)
FormLiquid
FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsMay also detect unidentified higher molecular weight proteins by immunoblotting. Maximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS cells with DNA damaging agents induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. This antibody can also immunoprecipitate proteins associated with p21WAF1. For immunoblotting applications, antigen/antibody complexes are best visualized using chemiluminescence. Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Yes
Toxicity Standard Handling
ReferencesAgarwal, M.L., et al. 1995 Proc. Natl. Acad. Sci. USA 92, 8493.
Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
Deng, C., et al. 1995 Cell 82, 675.
El-Deiry, W.S., et al. 1995 Cancer Res. 55, 2910.
Waldman, T., et al. 1995 Cancer Res. 55, 5187.
El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
Elbendary, A., et al. 1994 Cell Growth Diff. 5, 1301.
Li, R., et al. 1994 Nature 371, 534.
Michieli, P., et al. 1994 Cancer Res. 54, 3391.
Noda, A., et al.1994. Exp. Cell Res. 211, 90.
El-Deiry, W.S., et al. 1993. Cell 75 817.
Gu, Y., et al. 1993. Nature 366, 707.
Harper, J.W., et al. 1993 Cell 75, 805.
Xiong, Y., et al. 1993. Genes Devel. 7, 1572.
Xiong, Y., et al. 1993. Nature 366, 701.
Xiong, Y., et al. 1992. Cell 71, 505.
Application referencesEpitope Identification Patrick O'Connor (NCI, personal communication).